Nearly eight years after GlaxoSmithKline PLC's Benlysta (belimumab) became the first drug approved by the US Food and Drug Administration for lupus, the company is looking to expand the drug's indication to a substantial new subset of patients in the acute phase of the disease, even as the late-stage development space is heating up.
The company announced on 18 December positive data from a Phase III trial testing Benlysta in patients with lupus nephritis,...






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
